Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NBIX Neurocrine Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: NBIX
Price (delayed)
$127.6
Market cap
$12.63B
P/E Ratio
42.11
Dividend/share
N/A
EPS
$3.03
Enterprise value
$12.88B
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological
Highlights
The gross profit has grown by 22% YoY and by 2.4% from the previous quarter
Neurocrine Biosciences's revenue has increased by 22% YoY and by 2.4% QoQ
The price to earnings (P/E) is 57% lower than the 5-year quarterly average of 97.3 but 15% higher than the last 4 quarters average of 36.7
Neurocrine Biosciences's quick ratio has increased by 20% YoY but it has decreased by 9% from the previous quarter
NBIX's EPS is down by 20% year-on-year and by 11% since the previous quarter
The company's net income fell by 17% YoY and by 10% QoQ
Key stats
What are the main financial stats of NBIX
Market
Valuations
Earnings
Shares outstanding
98.97M
Market cap
$12.63B
Enterprise value
$12.88B
Price to earnings (P/E)
42.11
Price to book (P/B)
5.02
Price to sales (P/S)
5.27
EV/EBIT
27.63
EV/EBITDA
26.04
EV/Sales
5.34
Revenue
$2.41B
Gross profit
$2.38B
Operating income
$494.8M
Net income
$305.8M
EBIT
$466.2M
EBITDA
$494.7M
Free cash flow
$492.2M
Per share
Balance sheet
Liquidity
EPS
$3.03
EPS diluted
$2.95
Free cash flow per share
$4.94
Book value per share
$25.43
Revenue per share
$24.2
TBVPS
$36.62
Total assets
$3.69B
Total liabilities
$1.15B
Debt
$447.5M
Equity
$2.54B
Working capital
$1.12B
Debt to equity
0.18
Current ratio
3.13
Quick ratio
2.79
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
20.5%
Gross margin
98.5%
Net margin
12.7%
Operating margin
20.5%
Return on assets
8.6%
Return on equity
11.8%
Return on invested capital
14.6%
Return on capital employed
14.7%
Return on sales
19.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NBIX stock price
How has the Neurocrine Biosciences stock price performed over time
Intraday
-0.14%
1 week
0.23%
1 month
6.17%
1 year
-6.06%
YTD
-6.52%
QTD
15.37%
Financial performance
How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$2.41B
Gross profit
$2.38B
Operating income
$494.8M
Net income
$305.8M
Gross margin
98.5%
Net margin
12.7%
The net margin is down by 32% YoY and by 12% QoQ
The gross profit has grown by 22% YoY and by 2.4% from the previous quarter
Neurocrine Biosciences's revenue has increased by 22% YoY and by 2.4% QoQ
The company's net income fell by 17% YoY and by 10% QoQ
Price vs fundamentals
How does NBIX's price correlate with its fundamentals
Growth
What is Neurocrine Biosciences's growth rate over time
Valuation
What is Neurocrine Biosciences stock price valuation
P/E
42.11
P/B
5.02
P/S
5.27
EV/EBIT
27.63
EV/EBITDA
26.04
EV/Sales
5.34
The price to earnings (P/E) is 57% lower than the 5-year quarterly average of 97.3 but 15% higher than the last 4 quarters average of 36.7
NBIX's EPS is down by 20% year-on-year and by 11% since the previous quarter
NBIX's price to book (P/B) is 25% lower than its 5-year quarterly average of 6.7 but 2.4% higher than its last 4 quarters average of 4.9
The company's equity rose by 6% YoY but it fell by 2.1% QoQ
The stock's price to sales (P/S) is 28% less than its 5-year quarterly average of 7.3 and 4% less than its last 4 quarters average of 5.5
Neurocrine Biosciences's revenue has increased by 22% YoY and by 2.4% QoQ
Efficiency
How efficient is Neurocrine Biosciences business performance
The ROE has contracted by 33% YoY and by 12% from the previous quarter
Neurocrine Biosciences's return on assets has decreased by 29% YoY and by 11% QoQ
The company's return on invested capital fell by 24% YoY and by 8% QoQ
NBIX's return on sales is down by 19% year-on-year and by 6% since the previous quarter
Dividends
What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NBIX.
Financial health
How did Neurocrine Biosciences financials performed over time
The company's current ratio rose by 24% YoY but it fell by 8% QoQ
Neurocrine Biosciences's quick ratio has increased by 20% YoY but it has decreased by 9% from the previous quarter
The debt is 82% lower than the equity
NBIX's debt to equity is down by 14% year-on-year
The debt is down by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.